(Lung Cancer) Trastuzumab Deruxtecan in HER2-Mutant NSCLC: DESTINY-Lung02 Results
(Lung Cancer) Trastuzumab Deruxtecan in HER2-Mutant NSCLC: DESTINY-Lung02 Results
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Lung Cancer) Trastuzumab Deruxtecan in HER2-Mutant NSCLC: DESTINY-Lung02 Results
- September 27, 2023
- 1 min read
On September 11, 2023, Daiichi Sankyo presented results at the World Conference on Lung Cancer held in Singapore on the efficacy and safety of anti-HER2 antibody-drug conjugate in the DESTINY-Lung02 Phase II clinical trial for HER2-mutant advanced non-small cell lung cancer.
This trial enrolled previously treated HER2-mutant advanced non-small cell lung cancer patients and administered anti-HER2 antibody-drug conjugate at 5.4 mg/kg (N=102) and 6.4 mg/kg (N=50). The primary endpoint was objective response rate, and secondary endpoints included duration of response and overall survival.
The trial results showed that the primary endpoint objective response rate was: 49.0% for the 5.4 mg/kg group (1 complete response, 49 partial responses) and 56.0% for the 6.4 mg/kg group (2 complete responses, 26 partial responses).
The secondary endpoint median duration of response was: 16.8 months for the 5.4 mg/kg group / not reached for the 6.4 mg/kg group. The median progression-free survival was: 9.9 months for the 5.4 mg/kg group / 15.4 months for the 6.4 mg/kg group. The median overall survival was: 19.5 months for the 5.4 mg/kg group / not reached for the 6.4 mg/kg group.
Regarding safety, grade 3 or higher adverse events included neutropenia (5.4 mg/kg group 18.8% / 6.4 mg/kg group 36.0%) and anemia (5.4 mg/kg group 10.9% / 6.4 mg/kg group 16.0%). Although drug-related interstitial lung disease was observed (5.4 mg/kg group 12.9% / 6.4 mg/kg group 28.0%), most were low-grade adverse events. The grade 3 adverse event rates were: 5.4 mg/kg group 1.0% / 6.4 mg/kg group 0%, and grade 5 adverse event rates were: 5.4 mg/kg group 1.0% / 6.4 mg/kg group 2.0%.
Source: https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202309/20230911_J4.pdf
-
Investigational drug
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Results in Phase II Clinical Trial. (Lung Cancer) Is Anti-B7-H3 Antibody Drug DS-7300 Effective? (Lung Cancer) Is Alectinib Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.